Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 20/20 | 0.72 |
| ▸ | FGFR4 | P22455 | 20/20 | 0.72 |
| ▸ | FGFR3 | P22607 | 20/20 | 0.72 |
| ▸ | KDR | P35968 | 18/20 | 0.72 |
| ▸ | FLT3 | P36888 | 3/20 | 0.62 |
| ▸ | VEGFA | P15692 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23667664 | 0.90 | FGFR3 (0.62) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL23667658 | 0.89 | FGFR3 (0.73) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL23667665 | 0.88 | FGFR1 (0.65) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL16125154 | 0.87 | FGFR3 (0.77) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL23667291 | 0.86 | FGFR3 (0.77) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL23667656 | 0.84 | FGFR1 (0.71) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL16523111 | 0.84 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL23667659 | 0.83 | FGFR3 (0.62) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL23667663 | 0.83 | FGFR3 (0.63) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL23667660 | 0.81 | FGFR3 (0.66) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021146163-A1 | PYRIDAZINE AND 1,2,4-TRIAZINE DERIVATIVES AS FGFR KINASE INHIBITORS | BETA PHARMA, INC. (US) | 2021-07-22 | — | — | WO | disclosed |